Core Viewpoint - The announcement indicates a reduction in shareholding by Heilongjiang Chuangda Group Co., Ltd. due to the exchange of corporate bonds, resulting in a decrease in ownership percentage from 55.86% to 54.94% [1] Group 1 - Heilongjiang Chuangda Group Co., Ltd. has reduced its shareholding by 8.7097 million shares during the period from February 5 to February 9, 2026 [1] - After the equity change, Chuangda Group holds a total of 516,973,085 shares, representing 54.94% of the company's total equity [1]

Group 1 - The company announced that its controlling shareholder, Chuangda Group, notified it of an adjustment to the conversion price of the 2023 first phase convertible bond "23 Chuang 01EB" [1] - The bond has an issuance scale of 910 million yuan and a term of 3 years [1] - The conversion price will be automatically adjusted from 10.50 yuan per share to 8.80 yuan per share due to the stock price falling below 10 yuan per share for 10 out of 30 consecutive trading days during the conversion period [1]

Core Viewpoint - The report outlines a reduction in the shareholding of Heilongjiang Chuangda Group Co., Ltd. in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the conversion of exchangeable bonds, resulting in a decrease in ownership from 60.85% to 59.87% [19][21]. Group 1: Shareholding Changes - The shareholding of Heilongjiang Chuangda Group decreased by 0.98% due to the conversion of 9,223,963 shares from the exchangeable bonds "23 Chuang 01 EB" and "23 Chuang 02 EB" [5][21]. - As of the report date, Heilongjiang Chuangda Group holds 563,334,314 shares, representing 59.87% of the total share capital of the company [19][21]. - The total shares converted from both exchangeable bonds amount to 16,550,986 shares, accounting for 1.76% of the total share capital [21]. Group 2: Future Plans and Compliance - Heilongjiang Chuangda Group has no plans to increase or decrease its shareholding in the next 12 months, aside from the ongoing conversion of the exchangeable bonds [4][21]. - The report confirms that the shareholding change does not trigger a mandatory tender offer and will not alter the status of the controlling shareholder or actual controller [19][22]. - The company has complied with all relevant laws and regulations regarding the disclosure of this shareholding change [22].

Core Viewpoint - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. announced an adjustment to the conversion price of its convertible bond "23 Chuang 01 EB" to protect the interests of bondholders [1] Group 1: Bond Details - The convertible bond was issued on April 11, 2023, with a total scale of 910 million yuan and a maturity of 3 years [1] - The conversion price has been revised from 13.35 yuan per share to 12.35 yuan per share, effective from August 27 [1] Group 2: Corporate Actions - The adjustment was approved by the board of directors on August 11, and subsequently agreed upon in a bondholders' meeting on August 20 [1] - The pledged account for the shares still meets the conversion demand after the price adjustment [1]

Group 1 - The core point of the announcement is that the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., has experienced a change in equity that touches the 1% threshold due to the conversion of exchangeable bonds and the repurchase of restricted shares by the company [1][2]. - As of August 1, 2025, Heilongjiang Chuangda Group's shareholding in the company decreased from 61.56% to 60.85%, following the conversion of 7,327,023 shares during the exchange period from November 8, 2023, to August 1, 2025 [1][2]. - The equity change does not result in a change of the controlling shareholder or actual controller of the company, nor does it trigger a mandatory tender offer [2][3]. Group 2 - The exchangeable bonds issued by Chuangda Group are currently in the conversion period, and the decision of bondholders to convert their bonds into shares is uncertain [4]. - The company will fulfill its information disclosure obligations in accordance with laws and regulations if any further equity changes occur [4].

Core Viewpoint - The announcement details a change in the equity stake of the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., indicating a decrease in ownership percentage from 61.56% to 60.85% due to the repurchase and cancellation of restricted shares [1][2]. Group 1 - The controlling shareholder's equity stake decreased from 61.56% to 60.85% [1][2]. - The change in equity does not trigger mandatory tender offer obligations [1]. - The equity change is attributed to the repurchase and cancellation of restricted shares, which affected the total share capital of the company [2]. Group 2 - Heilongjiang Chuangda Group's shareholding decreased from 579,885,300 shares to 572,558,277 shares [1][2]. - The equity change occurred during the period of October 12, 2023, to December 8, 2023 [1]. - The company assures that the change in shareholding will not affect the status of the controlling shareholder or actual controller [2].